During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Dana-Farber Cancer Institute researchers will present key research studies at the 2025 Tandem Meetings, the premier ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

On this World Cancer Day, Chris Vogelsang, a cancer survivor from upstate New York, is celebrating his recovery thanks to a ...

Our Lady of the Lake Cancer Institute is celebrating after successfully completing a bone marrow transplant so rare it has ...

The future is bright for our bone marrow transplant program,” Dr. Hana Safah said. "We look forward to advancing blood cancer ...

China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...

Dana-Farber Cancer Institute researchers will present key research studies at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy.

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, ...